Jennifer Munson named director of Fralin Biomedical Research Institute at VTC's Cancer Research Center

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

Preclinical data on a development candidate, NTX-452, a novel Werner syndrome helicase inhibitor, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Nimbus Therapeutics.

October 25, 2024

Vol.50 No.40

Clinical Roundup

First-in-human study of novel inhibitor shows promise in MTAP-deleted solid tumors

AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses across patients with MTAP-deleted solid tumors, as well as an acceptable safety profile, according to first-in-human results of a dose-exploration/dose-expansion phase I study (NCT05094336) that were presented at the 2024 ESMO Congress.

October 04, 2024

Vol.50 No.37

Clinical Roundup

Immunological features predict treatment response for advanced solid tumors

The AMADEUS clinical trial sheds light on how biomarkers can predict how patients respond to immune checkpoint inhibitor treatments like nivolumab and ipilimumab.

September 13, 2024

Vol.50 No.34

In Brief

Cheng-Chia Wu joins Fralin Biomedical Research Institute at Virginia Tech Carilion

Cheng-Chia “Fred” Wu, a physician-scientist who treats brain tumors in children, has joined Virginia Tech to bring his expertise in focused ultrasound cancer research to the Fralin Biomedical Research Institute at Virginia Tech Carilion.

August 09, 2024

Vol.50 No.32

Clinical Roundup

Cancer cells salvage purine nucleotides—including dietary purines—to fuel tumor growth

Cancer cells salvage purine nucleotides to fuel tumor growth, including purines in foods we eat, an important discovery with implications for cancer therapies from research by Children’s Medical Center Research Institute at UT Southwestern published in Cell.

July 19, 2024

Vol.50 No.29

Clinical Roundup

Novel Co-STAR receptor shows promise treating cancers in preclinical study

Using genetic engineering techniques, investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center, the Lustgarten Laboratory and Bloomberg~Kimmel Institute for Cancer Immunotherapy have designed a novel type of cell to recognize and fight cancer.

July 12, 2024

Vol.50 No.28

Jennifer Munson named director of Fralin Biomedical Research Institute at VTC’s Cancer Research Center

YOU MAY BE INTERESTED IN

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

First-in-human study of novel inhibitor shows promise in MTAP-deleted solid tumors

Immunological features predict treatment response for advanced solid tumors

Cheng-Chia Wu joins Fralin Biomedical Research Institute at Virginia Tech Carilion

Cancer cells salvage purine nucleotides—including dietary purines—to fuel tumor growth

Novel Co-STAR receptor shows promise treating cancers in preclinical study

Renew today!

Subscriber content

Never miss an issue!

Login